Study of Gardasil in Mid-Adult Males (MAM)

This study is ongoing, but not recruiting participants.
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
H. Lee Moffitt Cancer Center and Research Institute Identifier:
First received: September 9, 2011
Last updated: March 13, 2015
Last verified: March 2015

The purpose of this study is to test the effectiveness of the research study vaccine, Gardasil, in men ages 27-45 who have completed 4 years of observation in The Human Papillomavirus [HPV] infection in men (HIM) Study.

Condition Intervention Phase
Human Papillomavirus
Biological: Gardasil
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: A Phase II Study of Gardasil in Human Papillomavirus Research The Mid-Adult Male Vaccine Study - The MAM STUDY

Further study details as provided by H. Lee Moffitt Cancer Center and Research Institute:

Primary Outcome Measures:
  • Number of Participants Who Sero-convert [ Time Frame: 7 Months ] [ Designated as safety issue: No ]
    Assess the percent of men who sero-convert to each of the 4 vaccine components 1 month post-dose 3 of vaccine. At Day 1 and Month 7, the seroconversion percentage to HPV 6/11/16/18 will be calculated separately as 100*(m/n), where n is number of participants contributing to the analyses and m is number of participants with the indicated response. Its 95% confidence interval (CI) will be calculated based on exact method.

Secondary Outcome Measures:
  • Number of Participants With Rise in Antibody Titers [ Time Frame: 7 Months ] [ Designated as safety issue: No ]
    Determine the rise in antibody titers 1 month post-dose 3 of vaccine. For each vaccine component, the geometric mean titers (GMT) and the corresponding 95% confidence intervals (CI) will be calculated for antibody titers at each time-point (Day 1 and Month 7). For each participant, the difference in antibody titers between these 2 time-points (titers at Month 7 minus titers at Day 1) will be calculated. If the data of the antibody titer difference is not normally distributed, then appropriate transformation will be conducted. The mean of antibody titer rise and its 95% CI will be calculated.

Enrollment: 150
Study Start Date: December 2012
Estimated Study Completion Date: October 2015
Primary Completion Date: May 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Gardasil Vaccine
Participants will be given a total of 3 injections (shots) at 3 separate visits.
Biological: Gardasil
The first shot will be given on the day they join the study (Visit 1). The second shot will be given about 2 months later (Visit 2) and the third shot will be given about 6 months after the first (Visit 3).
Other Name: HPV vaccine

Detailed Description:

The MAM Study is a prospective pilot intervention trial to investigate patterns of human papillomavirus (HPV) vaccine immunogenicity in men, aged 27-45 years, in which the men will receive Gardasil. Gardasil will be administered at 0, 2, and 6 months. Blood will be drawn at 0 and 7 months to provide a quadrivalent HPV antibody serologic profile. Each participant will also complete surveys (CASI) at Day 1 and Month 7 to record sexual behavior.

Our overall goal is to test the efficacy of Gardasil to reduce HPV 6, 11, 16, 18 persistent infection among men at the external genital epithelium, anal canal, and oral cavity, and to reduce lesions caused by these HPV types at the external genital epithelium and anal canal. The purpose of this Phase II trial is to establish the immunogenicity of Gardasil among mid-adult men and to establish the infrastructure with which to build the larger Phase III trial in the future.


Ages Eligible for Study:   27 Years to 45 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Men that have completed 4 years of follow-up in the on-going international prospective natural history study of HPV in men (The HIM Study)
  • Willing to comply with 4 scheduled visits within a 7-month period

Exclusion Criteria:

  • Have received an HPV vaccine
  • Have a prior diagnosis of penile or anal cancers
  • Have a prior diagnosis of high grade anal intraepithelial neoplasia
  • Have been diagnosed with human immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS)
  • Have a history of anaphylaxis to vaccines
  • Have known impairment of the immune system
  • Have received any blood products within 6 months of enrollment
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01432574

United States, Florida
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, United States, 33612
National Institute of Public Health, Mexico
Cuernavaca, Mexico, 62209
Sponsors and Collaborators
H. Lee Moffitt Cancer Center and Research Institute
Merck Sharp & Dohme Corp.
Principal Investigator: Anna Giuliano, Ph.D. H. Lee Moffitt Cancer Center and Research Institute
  More Information

Additional Information:
No publications provided

Responsible Party: H. Lee Moffitt Cancer Center and Research Institute Identifier: NCT01432574     History of Changes
Other Study ID Numbers: MCC-16593
Study First Received: September 9, 2011
Last Updated: March 13, 2015
Health Authority: United States: Food and Drug Administration

Keywords provided by H. Lee Moffitt Cancer Center and Research Institute:
HPV processed this record on May 21, 2015